Tickers

1. Composite Trajectory Verdict

Given BWXT's capital-intensive, contract-driven model spanning government defense and commercial nuclear/medical markets, all three statements carry roughly equal weight: the income statement reveals margin trajectory on long-duration contracts, the cash flow statement shows conversion of earnings given milestone billing and retainage dynamics, and the balance sheet reflects acquisition-driven leverage and goodwill accumulation.

Composite Trajectory: Mixed

Revenue, net income, EPS, and operating cash flow all improved year-over-year for three consecutive years (2023–2025). However, consolidated operating margin compressed from 15.3% (2023) to 14.1% (2024) to 12.6% (2025), with both segments showing margin decline. The balance sheet shifted markedly: long-term debt rose from $1.04B to $2.02B (driven by $1.25B of 0% convertible notes issued in November 2025), goodwill nearly doubled to $501M, and intangible assets doubled to $330M, while equity grew only 14%. Cash swelled to $500M and the new $1.25B revolving facility was undrawn, providing liquidity, but leverage (long-term debt/equity) rose from ~0.97x to ~1.64x.

2. Red Flags

• Operating margin compression despite revenue growth: Consolidated operating margin fell 270 bps over two years (15.3% → 12.6%) while revenue grew 28% (10-K 2025-12-31, Consolidated Statements of Operations). Government Operations margin declined from 18.4% to 16.8%; Commercial Operations margin fell from 8.9% to 6.8% (10-K 2025-12-31, MD&A Results of Operations).
• Acquisition integration costs recurring across segments: Government Operations incurred $13.1M of due diligence/post-acquisition integration/restructuring expenses; Commercial Operations incurred $19.9M of similar costs in 2025 (10-K 2025-12-31, MD&A Government Operations and Commercial Operations).
• Leverage step-up: Long-term debt increased 93% YoY to $2.016B at 12/31/2025, primarily from $1.25B 0% Convertible Senior Notes due 2030; debt/equity rose from ~0.97x to ~1.64x (10-K 2025-12-31, Balance Sheets; Note 6).
• Goodwill and intangibles now 19% of total assets: Goodwill $501M + intangibles $330M = $831M vs. total assets $4.27B at 12/31/2025, up from $453M vs. $2.87B at 12/31/2024 (10-K 2025-12-31, Balance Sheets; Note 1 Goodwill and Intangible Assets).
• Kinectrics purchase accounting incomplete: Fair value assessment "in process as of the filing date" with amounts "subject to change upon completion of purchase accounting, the impact of which may be material" (10-K 2025-12-31, Note 2).
• Pension/OPEB liability growth: Accumulated postretirement benefit obligation jumped from $16.5M to $78.5M; pension liability fell modestly from $82.6M to $78.2M but combined funded status deteriorated (10-K 2025-12-31, Balance Sheets; Note 7).
• Advance billings on contracts nearly doubled: From $161M to $305M, driving a $144M increase in contract liabilities (10-K 2025-12-31, Note 3 Contract Assets and Liabilities).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Revenue rose 18.3% YoY to $3.198B in 2025 (vs. $2.704B in 2024, $2.496B in 2023), driven by Government Operations (+7.7% to $2.350B) and Commercial Operations (+62.8% to $853M, largely from the Kinectrics acquisition) (10-K 2025-12-31, Consolidated Statements of Operations; MD&A). Net income attributable to BWXT grew 16.7% to $328.9M (vs. $281.9M in 2024, $245.8M in 2023); diluted EPS rose to $3.58 from $3.07 and $2.68 (10-K 2025-12-31, Consolidated Statements of Operations). However, consolidated operating income grew only 6.3% to $404.5M, lagging revenue growth, pushing operating margin down to 12.6% from 14.1% in 2024 and 15.3% in 2023. Government Operations operating margin fell to 16.8% from 17.3%; Commercial Operations margin fell to 6.8% from 8.9%. Unallocated corporate expenses rose to $48.1M from $44.1M. The effective tax rate declined to 17.1% from 19.0%, aided by R&D credits (10-K 2025-12-31, MD&A Provision for Income Taxes; Note 5).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Net cash provided by operating activities increased for the third consecutive year: $479.8M in 2025 vs. $408.4M in 2024 vs. $363.7M in 2023 (10-K 2025-12-31, Consolidated Statements of Cash Flows). Capital expenditures rose modestly to $184.6M from $153.6M and $151.3M, yielding free cash flow (operating less CapEx) of approximately $295M in 2025, up from ~$255M and ~$212M. Investing outflows surged to $742.1M in 2025 due to $535.1M of acquisition payments (A.O.T. and Kinectrics) vs. ~$155M in prior years. Financing activities flipped to a $693.6M inflow in 2025 (from -$252.8M in 2024) driven by $1.25B proceeds from the 2030 Notes, offset by $1.28B debt repayments (including the former credit facility), $131.9M capped call purchases, $30M share repurchases, and $92.5M dividends. Cash and equivalents ended 2025 at $500M vs. $74M at end-2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows; MD&A Liquidity).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets expanded 49% to $4.271B at 12/31/2025 from $2.870B at 12/31/2024, primarily from acquisition-related goodwill (+$214M to $501M), intangible assets (+$165M to $330M), PP&E (+$307M to $1.585B), and cash (+$426M to $500M) (10-K 2025-12-31, Balance Sheets; Note 1 Goodwill/Intangible Assets). Total liabilities grew 70% to $3.038B from $1.790B, led by long-term debt (+$973M to $2.016B) including the new $1.25B convertible notes, and higher contract liabilities (advance billings +$144M to $305M; retainages +$13M to $46M). Stockholders' equity rose 14% to $1.233B from $1.080B, as retained earnings growth ($236M) was partially offset by a $97.6M reduction for capped call purchases and $44.5M of treasury stock repurchases (10-K 2025-12-31, Balance Sheets; Statement of Stockholders' Equity). The new $1.25B revolving credit facility was undrawn at year-end with $1.249B available; the company was in compliance with all covenants (max net leverage 4.00x, min interest coverage 3.00x) (10-K 2025-12-31, Note 6 New Credit Facility).

6. Data Gaps

• Quarterly (10-Q) revenue, operating income, cash flow, and balance sheet figures for 2025-Q1 through 2026-Q2 to assess intra-year trajectory and seasonality (the provided filings list these 10-Qs but their contents are not included in the section).
• Segment-level quarterly revenue and operating income to see whether margin pressure is persistent or concentrated in post-acquisition quarters.
• Detailed breakout of Commercial Operations margin by organic vs. acquired (Kinectrics) components.
• Cash flow impact of the $144M advance billings increase (whether it reflects timing or structural shift).
• Post-2025 pension/OPEB cash contribution requirements beyond the disclosed $12.7M/$2.7M for 2026.
• Resolution of Kinectrics purchase accounting and any resulting goodwill/intangible adjustments.